AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy

The FDA granted accelerated approval for AstraZeneca’s Ultomiris to reduce proteinuria in adults with progressive-risk IgA nephropathy, making it the first and only C5 complement inhibitor approved in the U.S. for this indication. In the phase III I CAN study, Ultomiris reduced proteinuria by 43.4% versus placebo after 34 weeks; whether it slows kidney-function decline remains unestablished, pending longer-term results. Ultomiris sales rose 14% year over year to $2.58 billion in the first half of 2026, while AstraZeneca shares were down 7.4% year to date.

Analysis

The commercial read-through is more about expanding the addressable market for Ultomiris than a near-term change to AstraZeneca’s earnings profile: the drug already has a substantial sales base, while the IgAN contribution, uptake curve and net pricing are not yet disclosed. The key competitive distinction is endpoint, not simply mechanism. AZN’s approval rests on proteinuria reduction, overlapping directly with Novartis’ Fabhalta; Travere’s Filspari and Tarpeyo have claims tied to slowing kidney-function decline. Until eGFR benefit is demonstrated, physicians and payers may treat Ultomiris as an additional option rather than a replacement for therapies with kidney-function evidence. Its eight-week IV regimen may also constrain convenience versus alternatives, while offering a differentiated option for patients unsuitable for existing approaches.

The principal catalyst is the phase III I CAN eGFR readout at week 106, which could support traditional approval and strengthen durability claims. The downside is that a proteinuria response fails to translate into preserved kidney function, limiting uptake or putting the accelerated indication at risk. This is a months-to-years thesis, not a durable earnings catalyst on the approval headline alone. The contrarian point: “first and only C5 inhibitor” is a category distinction, not proof of superior clinical or economic value. AZN’s portfolio scale may mute the upside, while the read-through to competing IgAN assets is more relevant but not yet quantifiable without uptake, payer and trial-comparison data.

Key Decisions for Investors

• Do not chase AZN on the approval alone. Treat it as a modest pipeline/commercial positive; revisit only with evidence of meaningful new-patient starts, net pricing and incremental sales rather than conversion within the existing Ultomiris franchise.
• Track I CAN’s week-106 eGFR outcome as the decisive catalyst. A proteinuria benefit without kidney-function preservation would falsify the stronger long-term commercial thesis; confirmatory failure could also threaten the accelerated-approval pathway.
• For TVTX, monitor Filspari prescriptions, access and guidance for signs of share or pricing pressure. The threat is plausible but not yet a basis for a short absent evidence that clinicians are switching from kidney-function-focused treatment.
• For NVS, separate Fabhalta’s direct overlap on proteinuria from its broader portfolio exposure: watch comparative uptake and payer positioning before treating the AZN approval as a material negative.